Login to Your Account

Carmot's alchemy draws multiyear Amgen discovery deal

By Michael Fitzhugh
Staff Writer

Wednesday, December 6, 2017

Carmot Therapeutics Inc., a small-molecule lead-identification specialist and partner of Amgen Inc. since 2014, is extending its work for the Thousand Oaks, Calif.-based drugmaker to Parkinson's disease (PD) and other selected areas in a new multiyear deal. 

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription